Tarsus Pharmaceuticals, Inc. TARS Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s total liabilities & equity?
- Tarsus Pharmaceuticals, Inc. (TARS) reported total liabilities & equity of $581.14M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s total liabilities & equity changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s total liabilities & equity increased by 16.1% year-over-year, from $500.75M to $581.14M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s total liabilities & equity?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s total liabilities & equity has grown at a 26.7% compound annual growth rate (CAGR), from $171.97M to $562.16M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.